Tags

Type your tag names separated by a space and hit enter

Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.
Recent Pat CNS Drug Discov 2016; 10(2):157-177RP

Abstract

BACKGROUND

Starting from the chemical structure of phytocannabinoids, isolated from Cannabis sativa plant, research groups designed numerous cannabimimetic drugs. These compounds according to their activities can be partial, full agonists and antagonists of cannabinoid receptors. Anecdotal reports and scientific studies described beneficial properties of cannabinoids and their derivatives in several pathological conditions like neurological and neuropsychiatric disorders, and in many other diseases ranging from cancer, atherosclerosis, stroke, hypertension, inflammatory related disorders, and autoimmune diseases.

METHODS

In this study, starting from the endocannabinoid mechanism of action in neuronal signaling, we highlight and discuss potential application and recent patents of cannabimimetic drugs in neurological disorders.

RESULTS

The cannabinoid CB1 receptor was considered particularly interesting for therapeutic approaches in neurological diseases, because primarily expressed by neurons of the central nervous system. In many experimental models, these drugs act via this receptor, however, CB1 receptor independent mechanisms have been also described. Furthermore, endogenous ligands of cannabinoid receptors, the endocannabinoids, are potent modulators of the synaptic function in the brain. In neurological diseases, numerous studies reported modulation of the levels of endocannabinoids according to the phase of the disease and its progression.

CONCLUSIONS

Finally, although the study of the mechanisms of action of these compounds is still unsolved, many reports and patents strongly suggest therapeutic potential of these compounds in neurological diseases.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableNo affiliation info availableDepartment of Medicine and Surgery, University of Salerno, Via Salvatore Allende, Baronissi, 84081 Salerno, Italy and Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 84084 Fisciano (Salerno)- Italy. amalfitano@unisa.it.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27184693

Citation

Ranieri, Roberta, et al. "Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders." Recent Patents On CNS Drug Discovery, vol. 10, no. 2, 2016, pp. 157-177.
Ranieri R, Marasco D, Bifulco M, et al. Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders. Recent Pat CNS Drug Discov. 2016;10(2):157-177.
Ranieri, R., Marasco, D., Bifulco, M., & Malfitano, A. M. (2016). Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders. Recent Patents On CNS Drug Discovery, 10(2), pp. 157-177.
Ranieri R, et al. Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders. Recent Pat CNS Drug Discov. 2016;10(2):157-177. PubMed PMID: 27184693.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders. AU - Ranieri,Roberta, AU - Marasco,Daniela, AU - Bifulco,Maurizio, AU - Malfitano,Anna M, PY - 2015/12/21/received PY - 2016/02/22/revised PY - 2016/02/23/accepted PY - 2016/5/18/pubmed PY - 2017/7/14/medline PY - 2016/5/18/entrez SP - 157 EP - 177 JF - Recent patents on CNS drug discovery JO - Recent Pat CNS Drug Discov VL - 10 IS - 2 N2 - BACKGROUND: Starting from the chemical structure of phytocannabinoids, isolated from Cannabis sativa plant, research groups designed numerous cannabimimetic drugs. These compounds according to their activities can be partial, full agonists and antagonists of cannabinoid receptors. Anecdotal reports and scientific studies described beneficial properties of cannabinoids and their derivatives in several pathological conditions like neurological and neuropsychiatric disorders, and in many other diseases ranging from cancer, atherosclerosis, stroke, hypertension, inflammatory related disorders, and autoimmune diseases. METHODS: In this study, starting from the endocannabinoid mechanism of action in neuronal signaling, we highlight and discuss potential application and recent patents of cannabimimetic drugs in neurological disorders. RESULTS: The cannabinoid CB1 receptor was considered particularly interesting for therapeutic approaches in neurological diseases, because primarily expressed by neurons of the central nervous system. In many experimental models, these drugs act via this receptor, however, CB1 receptor independent mechanisms have been also described. Furthermore, endogenous ligands of cannabinoid receptors, the endocannabinoids, are potent modulators of the synaptic function in the brain. In neurological diseases, numerous studies reported modulation of the levels of endocannabinoids according to the phase of the disease and its progression. CONCLUSIONS: Finally, although the study of the mechanisms of action of these compounds is still unsolved, many reports and patents strongly suggest therapeutic potential of these compounds in neurological diseases. SN - 2212-3954 UR - https://www.unboundmedicine.com/medline/citation/27184693/Phytocannabinoids_and_Cannabimimetic_Drugs:_Recent_Patents_in_Central_Nervous_System_Disorders_ L2 - http://www.eurekaselect.com/142230/article DB - PRIME DP - Unbound Medicine ER -